Close Menu

NEW YORK – Following the announcement of a $60 million exclusive global license earlier this week, Veracyte is now gearing up to engage international markets using NanoString Technology's nCounter Flex platform. 

While Seattle-based NanoString retains the rights to commercialize the nCounter for research use applications, Veracyte will transition its current diagnostic and prognostic cancer assays onto the platform in order to reach a global audience. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.